4
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      The association between coffee consumption and bladder cancer in the bladder cancer epidemiology and nutritional determinants (BLEND) international pooled study

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          Inconsistent results for coffee consumption and bladder cancer (BC) risk have been shown in epidemiological studies. This research aims to increase the understanding of the association between coffee consumption and BC risk by bringing together worldwide case–control studies on this topic.

          Methods

          Data were collected from 13 case–control comprising of 5,911 cases and 16,172 controls. Pooled multivariate odds ratios (ORs), with corresponding 95% confidence intervals (CIs), were obtained using multilevel logistic regression models. Furthermore, linear dose–response relationships were examined using fractional polynomial models.

          Results

          No association of BC risk was observed with coffee consumption among smokers. However, after adjustment for age, gender, and smoking, the risk was significantly increased for never smokers (ever vs. never coffee consumers: OR model2 1.30, 95% CI 1.06–1.59; heavy (> 4 cups/day) coffee consumers vs. never coffee consumers: OR model2 1.52, 95% CI 1.18–1.97, p trend = 0.23). In addition, dose–response analyses, in both the overall population and among never smokers, also showed a significant increased BC risk for coffee consumption of more than four cups per day. Among smokers, a significant increased BC risk was shown only after consumption of more than six cups per day.

          Conclusion

          This research suggests that positive associations between coffee consumption and BC among never smokers but not smokers.

          Related collections

          Most cited references98

          • Record: found
          • Abstract: found
          • Article: not found

          Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.

          Estimates of the worldwide incidence and mortality from 27 major cancers and for all cancers combined for 2012 are now available in the GLOBOCAN series of the International Agency for Research on Cancer. We review the sources and methods used in compiling the national cancer incidence and mortality estimates, and briefly describe the key results by cancer site and in 20 large "areas" of the world. Overall, there were 14.1 million new cases and 8.2 million deaths in 2012. The most commonly diagnosed cancers were lung (1.82 million), breast (1.67 million), and colorectal (1.36 million); the most common causes of cancer death were lung cancer (1.6 million deaths), liver cancer (745,000 deaths), and stomach cancer (723,000 deaths). © 2014 UICC.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: found

            Cancer Statistics, 2017.

            Each year, the American Cancer Society estimates the numbers of new cancer cases and deaths that will occur in the United States in the current year and compiles the most recent data on cancer incidence, mortality, and survival. Incidence data were collected by the Surveillance, Epidemiology, and End Results Program; the National Program of Cancer Registries; and the North American Association of Central Cancer Registries. Mortality data were collected by the National Center for Health Statistics. In 2017, 1,688,780 new cancer cases and 600,920 cancer deaths are projected to occur in the United States. For all sites combined, the cancer incidence rate is 20% higher in men than in women, while the cancer death rate is 40% higher. However, sex disparities vary by cancer type. For example, thyroid cancer incidence rates are 3-fold higher in women than in men (21 vs 7 per 100,000 population), despite equivalent death rates (0.5 per 100,000 population), largely reflecting sex differences in the "epidemic of diagnosis." Over the past decade of available data, the overall cancer incidence rate (2004-2013) was stable in women and declined by approximately 2% annually in men, while the cancer death rate (2005-2014) declined by about 1.5% annually in both men and women. From 1991 to 2014, the overall cancer death rate dropped 25%, translating to approximately 2,143,200 fewer cancer deaths than would have been expected if death rates had remained at their peak. Although the cancer death rate was 15% higher in blacks than in whites in 2014, increasing access to care as a result of the Patient Protection and Affordable Care Act may expedite the narrowing racial gap; from 2010 to 2015, the proportion of blacks who were uninsured halved, from 21% to 11%, as it did for Hispanics (31% to 16%). Gains in coverage for traditionally underserved Americans will facilitate the broader application of existing cancer control knowledge across every segment of the population. CA Cancer J Clin 2017;67:7-30. © 2017 American Cancer Society.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: found

              Global cancer statistics.

              The global burden of cancer continues to increase largely because of the aging and growth of the world population alongside an increasing adoption of cancer-causing behaviors, particularly smoking, in economically developing countries. Based on the GLOBOCAN 2008 estimates, about 12.7 million cancer cases and 7.6 million cancer deaths are estimated to have occurred in 2008; of these, 56% of the cases and 64% of the deaths occurred in the economically developing world. Breast cancer is the most frequently diagnosed cancer and the leading cause of cancer death among females, accounting for 23% of the total cancer cases and 14% of the cancer deaths. Lung cancer is the leading cancer site in males, comprising 17% of the total new cancer cases and 23% of the total cancer deaths. Breast cancer is now also the leading cause of cancer death among females in economically developing countries, a shift from the previous decade during which the most common cause of cancer death was cervical cancer. Further, the mortality burden for lung cancer among females in developing countries is as high as the burden for cervical cancer, with each accounting for 11% of the total female cancer deaths. Although overall cancer incidence rates in the developing world are half those seen in the developed world in both sexes, the overall cancer mortality rates are generally similar. Cancer survival tends to be poorer in developing countries, most likely because of a combination of a late stage at diagnosis and limited access to timely and standard treatment. A substantial proportion of the worldwide burden of cancer could be prevented through the application of existing cancer control knowledge and by implementing programs for tobacco control, vaccination (for liver and cervical cancers), and early detection and treatment, as well as public health campaigns promoting physical activity and a healthier dietary intake. Clinicians, public health professionals, and policy makers can play an active role in accelerating the application of such interventions globally.
                Bookmark

                Author and article information

                Journal
                9100846
                1173
                Cancer Causes Control
                Cancer Causes Control
                Cancer causes & control : CCC
                0957-5243
                1573-7225
                30 March 2022
                August 2019
                30 May 2019
                06 April 2022
                : 30
                : 8
                : 859-870
                Affiliations
                [1 ]NUTRIM School for Nutrition and Translational Research in Metabolism, University of Maastricht, Universiteitssingel 40 (Room C5.564), 6229 ER Maastricht, The Netherlands
                [2 ]CAPHRI School for Public Health and Primary Care, University of Maastricht, Maastricht, The Netherlands
                [3 ]Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK
                [4 ]Department of Preventive Medicine, University of Southern California, Los Angeles, CA, USA
                [5 ]Leuven University Centre for Cancer Prevention (LUCK), Louvain, Belgium
                [6 ]Department of Urology, Buddhist Dalin Tzu Chi General Hospital, Dalin Township, Chiayi County, Taiwan
                [7 ]Leibniz Institute for Prevention Research and Epidemiology-BIPS, Bremen, Germany
                [8 ]Clinical Cancer Epidemiology, Department of Oncology, Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
                [9 ]Department of Cancer Prevention and Control, Roswell Park Cancer Institute, Buffalo, NY, USA
                [10 ]Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, Section of Public Health and Human Sciences, University of Brescia, Brescia, Italy
                [11 ]Department of Clinical Medicine and Community Health, University of Milan, Milan, Italy
                [12 ]Department of Epidemiology and Community Medicine, University of Ottawa, Ottawa, ON, Canada
                [13 ]INSERM U946, Variabilite Genetique et Maladies Humaines, Fondation Jean Dausset/CEPH, Paris, France
                [14 ]Departments of Epidemiology, UCLA Center for Environmental Genomics, Fielding School of Public Health, University of California, Los Angeles (UCLA), Los Angeles, CA, USA
                [15 ]Laboratory of Oncology, Istituto di Ricerche Farmacologiche “Mario Negri” IRCCS, Milan, Italy
                [16 ]Epidemiology Branch and Epigenetic and Stem Cell Biology Laboratory, National Institute of Environmental Health Sciences, NIH, Research Triangle Park, NC, USA
                Author notes

                Author contributions Study conception and design: AW and MPZ; Analyses and interpretation of data: EYY and FVO; Drafting of the manuscript: EYY; Revised the manuscript: AW, FVO, and MPZ; Provided the data: MCS, XJ, EK, CML, HP, GS, JM, MFA, CLV, KCJ, SB, ZFZ, CB, JAT, and MPZ; Approved the manuscript: all authors.

                Author information
                http://orcid.org/0000-0001-7825-5087
                Article
                NIHMS1615821
                10.1007/s10552-019-01191-1
                8985651
                31147895
                c3cb2ddd-47ec-4dc3-aa5e-546533c12cd6

                Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License ( http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

                History
                Categories
                Article

                Oncology & Radiotherapy
                bladder cancer,coffee consumption,smoking,dose–response analyses,population-attributable risk

                Comments

                Comment on this article